GIP/GLP-1 Dual Agonists: Class Overview Monograph

What Is the GIP/GLP-1 Dual Agonist Drug Class?

GIP/GLP-1 dual agonists are a class of incretin-based peptide drugs designed to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide, the prototype, is a 39-amino-acid synthetic peptide with structural homology to native GIP. It was engineered with fatty-acid modification to extend the plasma half-life to approximately five days, enabling once-weekly subcutaneous dosing [1].

How Dual Agonism Differs from GLP-1 Monotherapy

GLP-1 receptor agonists such as semaglutide act on a single receptor. Adding GIP receptor activity produces effects that are distinct from additive. The GIP receptor modulates adipocyte lipid metabolism, enhances insulin secretion in a glucose-dependent manner, and may reduce the nausea signaling associated with GLP-1 receptor activation in the area postrema [2]. This combination partly explains why tirzepatide achieves greater weight loss than the highest approved dose of semaglutide in head-to-head data from SURMOUNT-5 (N=751), where tirzepatide 10 mg or 15 mg produced 20.2% mean weight loss vs. 13.7% with semaglutide 2.4 mg at 72 weeks (P<0.001) [3].

Receptor Binding Profile

Tirzepatide binds the GIP receptor with affinity approximately equal to native GIP, and binds the GLP-1 receptor with lower affinity than native GLP-1. This intentionally biased binding is believed to minimize the GLP-1-mediated emetic signaling while preserving glucose-lowering and appetite-suppression effects [1]. No currently approved agent in this class has pure GIP agonism without GLP-1 activity.

Approved Indications and Regulatory History

The FDA granted four approvals for tirzepatide across 2022 to 2024, making it the most rapidly expanded single-molecule incretin therapy in regulatory history.

Type 2 Diabetes (Mounjaro, May 2022)

The SURPASS clinical trial program supported the T2DM approval. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly over 40 weeks [4]. Tirzepatide at 15 mg reduced HbA1c by 2.3 percentage points vs. 1.86 percentage points for semaglutide 1 mg (P<0.001). The proportion of participants achieving HbA1c <5.7% was 27% in the tirzepatide 15 mg arm vs. 6% in the semaglutide arm [4]. The FDA label for Mounjaro covers adjunctive use with diet and exercise in adults with T2DM, with no restriction on background therapy.

Chronic Weight Management (Zepbound, November 2023)

SURMOUNT-1 (N=2,539) enrolled adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, without diabetes [5]. At 72 weeks, mean weight loss was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs. 3.1% placebo. The tirzepatide 15 mg group lost a mean of 22.5 kg of body weight. 89.5% of participants in the 15 mg arm achieved ≥5% weight loss vs. 34.4% placebo (P<0.001) [5]. Zepbound is approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, dyslipidemia, T2DM, obstructive sleep apnea, or cardiovascular disease).

Obstructive Sleep Apnea (Zepbound, December 2024)

SURMOUNT-OSA (two trials; N=469 combined) enrolled adults with moderate-to-severe OSA and obesity [6]. Tirzepatide 10 mg or 15 mg weekly reduced the apnea-hypopnea index (AHI) by 27.4 to 29.3 events per hour vs. Reductions of 4.8 to 5.3 events per hour with placebo at 52 weeks [6]. This is the first FDA approval of a pharmacologic agent specifically for obesity-related OSA. The label requires BMI ≥30 kg/m² and may be used with or without positive airway pressure therapy.

Heart Failure with Preserved Ejection Fraction (Zepbound, March 2024)

The SUMMIT trial (N=731) enrolled patients with HFpEF (ejection fraction ≥50%) and BMI ≥30 kg/m² [7]. Tirzepatide significantly improved the primary endpoint of a win ratio composite of cardiovascular death, worsening heart failure events, and change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS). The KCCQ-CSS improvement was 6.9 points greater with tirzepatide vs. Placebo (P<0.001), alongside 15.7% mean weight loss at 52 weeks [7]. This approval expanded tirzepatide's label beyond metabolic indications into a dedicated cardiovascular indication.

Pharmacology and Mechanism of Action

Incretin Physiology Background

Incretins are gut-derived hormones released postprandially. GLP-1, secreted primarily from L-cells in the distal ileum, stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central pathways [2]. GIP, secreted from K-cells in the proximal duodenum and jejunum, also potentiates insulin secretion and has anabolic effects on bone and adipose tissue. In people with T2DM, the GIP incretin effect is substantially preserved, whereas GLP-1 incretin effect is reduced, making GIP receptor engagement particularly relevant to this population [2].

Tirzepatide's Molecular Design

The tirzepatide molecule uses the GIP peptide backbone as the scaffold, with a C20 fatty diacid moiety attached at lysine-26 via a linker. This modification enables albumin binding, extending half-life to approximately 5 days and supporting once-weekly dosing [1]. The molecule activates both receptors in a glucose-dependent manner, meaning insulin secretion is amplified when blood glucose is elevated, reducing hypoglycemia risk compared to sulfonylureas.

Weight Loss Mechanisms

Three pathways account for tirzepatide's weight-reduction effect. First, hypothalamic GLP-1 receptor activation reduces caloric intake by approximately 20 to 30% in clinical studies. Second, GIP receptor activation in adipocytes shifts lipid partitioning and increases energy expenditure. Third, slower gastric emptying prolongs satiety signaling [5]. Body composition analyses from SURMOUNT-1 showed that roughly 67% of lost mass was fat mass as measured by DEXA, with 33% lean mass, a ratio comparable to bariatric surgery outcomes [5].

Dosing and Administration

Standard Titration Schedule

Tirzepatide is available as a single-dose prefilled autoinjector (Zepbound) and prefilled pen (Mounjaro) in 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths. The FDA-approved titration for both indications begins at 2.5 mg subcutaneously once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, to a maintenance dose of 5, 10, or 15 mg weekly [1]. The 2.5 mg dose is a titration dose only and is not considered therapeutically effective for weight loss or glycemic control. Maximum approved dose is 15 mg weekly.

Injection Site and Storage

Injections are administered subcutaneously in the abdomen, thigh, or upper arm. Rotation of injection sites is recommended. Product must be stored refrigerated at 2 to 8°C; it may be stored at room temperature (up to 30°C) for a maximum of 21 days [1]. Freezing renders the product unusable.

Renal and Hepatic Considerations

No dose adjustment is required for any degree of renal impairment, including end-stage renal disease, per the FDA prescribing information [1]. Limited data exist in severe hepatic impairment; use is not contraindicated but requires clinical judgment. Tirzepatide is not removed by hemodialysis.

Missed Dose Management

If a dose is missed and fewer than 4 days (96 hours) remain until the next scheduled dose, skip the missed dose and resume the regular schedule. If more than 4 days have passed since the missed dose, administer as soon as possible and resume the weekly schedule [1].

Safety Profile and Adverse Effects

Gastrointestinal Adverse Effects

GI adverse events are the most common reason for tirzepatide discontinuation. In SURMOUNT-1, nausea occurred in 32% of participants (15 mg arm) vs. 9% placebo; vomiting in 18% vs. 2%; diarrhea in 23% vs. 9% [5]. Most events were mild to moderate and occurred during dose escalation. The slower titration protocol introduced in later trials reduced discontinuation rates to approximately 5 to 7%.

Prescribers should advise patients to eat smaller meals, avoid high-fat foods during titration, and stay hydrated. Anti-emetic pre-medication is not routinely recommended but may be used in individual cases.

Thyroid C-Cell Tumor Risk

The FDA black box warning for tirzepatide notes that GLP-1 receptor agonism caused thyroid C-cell tumors (C-cell hyperplasia and medullary thyroid carcinoma) in rodent studies at clinically relevant exposures [1]. Relevance to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Routine calcitonin monitoring is not required by labeling but may be considered at the prescriber's discretion.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 class drugs. The FDA label advises discontinuation if pancreatitis is suspected. Patients with a history of pancreatitis were excluded from SURPASS and SURMOUNT trials, so incidence data in this subgroup are unavailable [1]. Prescribers should assess baseline risk before initiating therapy.

Hypoglycemia

When tirzepatide is used as monotherapy or with metformin, hypoglycemia rates are low. SURPASS-2 reported symptomatic hypoglycemia in 0.6% (tirzepatide 15 mg) vs. 0.2% (semaglutide 1 mg) [4]. Risk increases significantly when tirzepatide is combined with insulin secretagogues or insulin; dose reductions of those agents are usually necessary at initiation.

Gallbladder Disease

Rapid weight loss is associated with cholelithiasis. In SURMOUNT-1, gallbladder-related adverse events occurred in 1.8% of tirzepatide participants vs. 0.8% placebo [5]. Patients with prior biliary disease should be counseled before starting therapy.

Diabetic Retinopathy

Rapid improvement in glycemic control may transiently worsen diabetic retinopathy, a phenomenon also observed with insulin intensification. SURPASS trials reported retinopathy-related events in 0.3 to 1.0% of participants; ophthalmologic evaluation before initiation is reasonable in patients with pre-existing retinopathy [4].

Comparative Efficacy Within and Across Classes

Tirzepatide vs. Semaglutide 2.4 mg

SURMOUNT-5 (N=751, 72 weeks) is the only published head-to-head randomized trial comparing tirzepatide directly to semaglutide 2.4 mg in adults with obesity without diabetes [3]. Tirzepatide (10 or 15 mg) produced 20.2% mean body-weight loss vs. 13.7% with semaglutide 2.4 mg (difference: 6.5 percentage points, P<0.001). 31.6% of the tirzepatide group achieved ≥25% weight loss vs. 8.7% in the semaglutide group [3]. These differences are clinically meaningful; each 5% increment in weight loss confers additional improvements in blood pressure, lipids, and glycemia.

Tirzepatide vs. Semaglutide 1 mg (T2DM)

In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.3% vs. 1.86% for semaglutide 1 mg, and produced 11.2 kg vs. 6.2 kg weight loss [4]. This superiority is consistent across the SURPASS program, which tested tirzepatide against insulin degludec (SURPASS-3), insulin glargine (SURPASS-4), and as combination therapy with insulin (SURPASS-AP-Combo).

Positioning Within Incretin Therapy Hierarchy

Based on published efficacy data, a practical prescribing hierarchy for incretin-based agents in adults with obesity or T2DM and cardiovascular risk looks like this: GLP-1 monotherapy (semaglutide 1 mg or 2.4 mg) occupies the first rung when cost or access constraints apply. GIP/GLP-1 dual agonism (tirzepatide) occupies the next rung when maximum weight loss or HbA1c reduction is the priority and access allows. Future triple agonists (GIP/GLP-1/glucagon) are in Phase 3 development but not yet approved. Prescribers should revisit positioning whenever new head-to-head or outcomes trial data are published, as the class is evolving rapidly.

As the American Diabetes Association's 2024 Standards of Medical Care states: "For patients with type 2 diabetes who need greater glucose lowering and weight reduction, tirzepatide has demonstrated superior HbA1c and body weight reduction compared to semaglutide 1 mg" [8].

Prescribing Considerations for Special Populations

Patients with Chronic Kidney Disease

Tirzepatide does not require dose adjustment in CKD stages 1 through 5 or in dialysis patients [1]. Volume depletion from GI adverse effects can transiently reduce GFR; monitoring creatinine during the first 8 to 12 weeks of therapy is prudent, particularly in patients already at risk for acute kidney injury.

Patients on Oral Medications with Narrow Therapeutic Index

Tirzepatide slows gastric emptying, which can delay peak plasma concentrations of oral drugs taken concurrently. Drugs with narrow therapeutic indices (warfarin, tacrolimus, levothyroxine, oral contraceptives) may be affected. The FDA label recommends monitoring for therapeutic effects of drugs that are particularly sensitive to delayed absorption [1].

Pediatric Use

Tirzepatide is not currently approved for use in patients under 18 years of age. No published pediatric pharmacokinetic or efficacy data exist as of mid-2025.

Pregnancy and Lactation

Tirzepatide is teratogenic in animal studies at exposures below the maximum human dose. It must be discontinued at least 2 months before a planned pregnancy, given the approximately 5-day half-life and the need for complete washout [1]. No human lactation data are available; breastfeeding is not recommended during treatment.

Monitoring and Follow-Up Protocol

Baseline Assessment Before Starting

Before initiating tirzepatide, clinicians should document: fasting glucose and HbA1c, comprehensive metabolic panel, lipid panel, thyroid function if clinically indicated, personal and family history of MTC or MEN 2, history of pancreatitis, and baseline body weight with BMI calculation. Ophthalmologic review is advisable in patients with diagnosed diabetic retinopathy.

On-Treatment Monitoring

Body weight should be assessed at weeks 4, 8, and 12, then every 12 weeks thereafter. At 12 weeks on a therapeutically effective dose (5 mg or higher), patients who have not achieved ≥5% weight loss are unlikely to be sustained responders; the FDA Zepbound label suggests discontinuation if this threshold is not met [1]. HbA1c should be checked every 3 months until stable in the T2DM setting.

Patients on concomitant insulin or sulfonylureas need glucose monitoring intensification during the first 4 to 8 weeks; dose reductions of insulin by 20 to 50% are often required.

Discontinuation and Rebound Considerations

Weight regain after stopping tirzepatide follows a predictable pattern. SURMOUNT-4 (N=670) demonstrated that participants who completed 36 weeks of tirzepatide and were then randomized to placebo for 52 additional weeks regained a mean of 14 percentage points of body weight, compared to continued weight loss of 5.5% in the tirzepatide continuation group [9]. This trial establishes that obesity behaves as a chronic condition requiring sustained pharmacotherapy, not a temporary one corrected by a finite course of treatment.

Drug Interactions and Combination Therapy

Combinations with Insulin

Combining tirzepatide with basal insulin is effective in T2DM but increases hypoglycemia risk. SURPASS-AP-Combo (N=1,048) showed adding tirzepatide to insulin glargine reduced HbA1c by 2.1% (15 mg) vs. 0.2% for placebo, with severe hypoglycemia in 1.7% of the tirzepatide group [10]. Insulin dose reduction at initiation is standard practice.

Combinations with SGLT-2 Inhibitors

No dedicated interaction trial has been published, but observational and sub-group data suggest additive weight loss and blood pressure reduction. The combination is mechanistically complementary because SGLT-2 inhibitors reduce glucose through renal glycosuria rather than insulin-mediated pathways.

Combinations with Metformin

The combination of tirzepatide and metformin is the most studied non-insulin combination. No pharmacokinetic interaction exists. Metformin may attenuate the vitamin B12 depletion that can occur with long-term metformin use and remains relevant in patients continuing both agents.

Access, Cost, and Prior Authorization

List prices for Zepbound (2025) range from approximately $1,059 per month (2.5 mg and 5 mg pens) to $1,086 per month (7.5 to 15 mg pens) in the United States. A Zepbound Savings Card program reduces cost for commercially insured patients to a stated $25 per month for eligible patients, though eligibility criteria apply. Medicare Part D currently does not cover Zepbound for the obesity indication following the 2006 exclusion of weight-loss drugs from Part D, though the TREATS Act legislation was pending in Congress as of mid-2025.

Prior authorization criteria across major commercial payers typically require: documented BMI meeting label criteria, documentation of a weight-related comorbidity (for BMI ≥27 patients), a previous trial of lifestyle intervention, and absence of contraindications.

Biosimilars and generic versions of tirzepatide are not expected before 2036 based on current patent expiration projections.